Vineet Agarwal
Net worth: - $ as of 31/05/2024
Profile
Vineet Agarwal is currently the Chief Financial Officer at Korro Bio, Inc. (United States) since 2021.
He is also the Treasurer, Chief Financial & Accounting Officer at Korro Bio, Inc. since 2023.
Previously, he worked as the Executive Director-Biotech Investment Banking at 09143628 Ltd.
from 2019 to 2021.
He also held the position of Executive Director at JPMorgan Chase & Co. from 2019 to 2021.
Mr. Agarwal holds an MBA from the Institute of Management Technology and an undergraduate degree from Shri Ram College of Commerce.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
-.--% | 17/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Vineet Agarwal active positions
Companies | Position | Start |
---|---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 01/05/2021 |
Former positions of Vineet Agarwal
Companies | Position | End |
---|---|---|
09143628 Ltd. | Corporate Officer/Principal | 01/05/2021 |
JPMORGAN CHASE & CO. | Director/Board Member | 01/05/2021 |
Training of Vineet Agarwal
Institute of Management Technology | Masters Business Admin |
Shri Ram College of Commerce | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
JPMORGAN CHASE & CO. | Finance |
Private companies | 2 |
---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
09143628 Ltd. | Finance |
- Stock Market
- Insiders
- Vineet Agarwal